Brainomix Extends Series C Financing To $25.4M To Support U.S. Expansion

This follows the £14 million raised in March 2025 bringing the total round to £18.8 million (c. $25.4 million).

The extension was led by existing investors Parkwalk Advisors and Hostplus via the IP Group Hostplus Innovation Fund, with participation from new U.S.-based investor Modi Ventures.

With established U.S. operations and an extensive portfolio of FDA-cleared AI imaging solutions, Brainomix will use the additional capital to accelerate its expansion in the U.S. market. The funding will support broader deployment of its AI platforms Brainomix 360 Stroke and e-Lung across multiple hospitals.

Read Also - Clee Medical Raises Seed Funding to Advance Real-Time Brain Imaging

Led by CEO Dr. Michalis Papadakis, Brainomix specializes in AI-driven medical imaging to enable precision medicine in stroke and lung fibrosis. Its flagship Brainomix 360 Stroke platform provides automated AI imaging for acute stroke assessment throughout the patient pathway, supporting faster and more confident treatment and transfer decisions regardless of hospital resources.

The e-Lung platform applies AI-powered CT biomarkers to identify, monitor, and predict disease progression in pulmonary fibrosis.

Founded as a spinout from the University of Oxford, Brainomix operates across the UK, Ireland, and the U.S., with a presence in more than 20 countries.

"This investment reflects strong confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care," said Dr Michalis Papadakis, CEO and co-founder of Brainomix.

"Stroke care depends on speed while lung fibrosis care requires early identification and consistent clinical decision making over time underscoring the need for hospital technologies that support clinicians at the point of care. With this investment extension we are well-positioned to enhance customer support across the US and Europe accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments."

Sahir Ali, founder and general partner of Modi Ventures, added, "Brainomix has built an exceptionally strong platform backed by rigorous clinical validation and real-world evidence showing that Brainomix 360 Stroke can significantly increase endovascular thrombectomy treatment rates and reduce delays in patient triage and transfer, particularly in primary stroke centers. With e-Lung, Brainomix is developing a truly novel technology to accelerate the diagnosis of fibrosing lung disease, enabling earlier treatment options that can improve patient outcomes. We are pleased to join as a new investor and look forward to supporting the company as it expands in the U.S. and accelerates adoption of technologies that meaningfully improve patient outcomes."

About Brainomix

Founded in 2010 as a spinout from the University of Oxford Brainomix develops AI-powered imaging biomarkers and software that transform routine scans into actionable insights. Focused on stroke and lung care, its precision medicine solutions help physicians worldwide make faster, more confident, life-saving treatment decisions.